132 related articles for article (PubMed ID: 37208212)
1. Frequency of use and cost of biologic treatment for inflammatory bowel disease and inflammatory bowel disease-associated arthropathy in Colombia in 2019.
Fernández-Ávila DG; Dávila-Ruales V
Rev Gastroenterol Mex (Engl Ed); 2024; 89(2):213-221. PubMed ID: 37208212
[TBL] [Abstract][Full Text] [Related]
2. The cost-effectiveness of biologic versus non-biologic treatments and the health-related quality of life among a sample of patients with inflammatory bowel disease in a tertiary care center in Saudi Arabia.
AlRuthia Y; Almadi M; Aljebreen A; Azzam N; Alsharif W; Alrasheed H; Almuaythir G; Saeed M; HajkhderMullaissa B; Alharbi O
J Med Econ; 2020 Oct; 23(10):1102-1110. PubMed ID: 32619388
[TBL] [Abstract][Full Text] [Related]
3. The Impact of Inflammatory Bowel Disease in Canada 2018: Direct Costs and Health Services Utilization.
Kuenzig ME; Benchimol EI; Lee L; Targownik LE; Singh H; Kaplan GG; Bernstein CN; Bitton A; Nguyen GC; Lee K; Cooke-Lauder J; Murthy SK
J Can Assoc Gastroenterol; 2019 Feb; 2(Suppl 1):S17-S33. PubMed ID: 31294382
[TBL] [Abstract][Full Text] [Related]
4. Market share and costs of biologic therapies for inflammatory bowel disease in the USA.
Yu H; MacIsaac D; Wong JJ; Sellers ZM; Wren AA; Bensen R; Kin C; Park KT
Aliment Pharmacol Ther; 2018 Feb; 47(3):364-370. PubMed ID: 29164650
[TBL] [Abstract][Full Text] [Related]
5. Health-care costs of inflammatory bowel disease in a pan-European, community-based, inception cohort during 5 years of follow-up: a population-based study.
Burisch J; Vardi H; Schwartz D; Friger M; Kiudelis G; Kupčinskas J; Fumery M; Gower-Rousseau C; Lakatos L; Lakatos PL; D'Incà R; Sartini A; Valpiani D; Giannotta M; Arebi N; Duricova D; Bortlik M; Chetcuti Zammit S; Ellul P; Pedersen N; Kjeldsen J; Midjord JMM; Nielsen KR; Winther Andersen K; Andersen V; Katsanos KH; Christodoulou DK; Domislovic V; Krznaric Z; Sebastian S; Oksanen P; Collin P; Barros L; Magro F; Salupere R; Kievit HAL; Goldis A; Kaimakliotis IP; Dahlerup JF; Eriksson C; Halfvarson J; Fernandez A; Hernandez V; Turcan S; Belousova E; Langholz E; Munkholm P; Odes S;
Lancet Gastroenterol Hepatol; 2020 May; 5(5):454-464. PubMed ID: 32061322
[TBL] [Abstract][Full Text] [Related]
6. Changes in Direct Healthcare Costs before and after the Diagnosis of Inflammatory Bowel Disease: A Nationwide Population-Based Study.
Lee J; Im JP; Han K; Kim J; Lee HJ; Chun J; Kim JS
Gut Liver; 2020 Jan; 14(1):89-99. PubMed ID: 31158951
[No Abstract] [Full Text] [Related]
7. Adherence to subcutaneous biologic treatment for inflammatory bowel disease.
Ramos L; Ramos-Rodríguez J; Barreda R; Gutiérrez-Nicolás F; Carrillo-Palau M; Alonso-Abreu I; Nazco-Casariego J; Quintero E
Gastroenterol Hepatol; 2022 May; 45(5):335-341. PubMed ID: 34051312
[TBL] [Abstract][Full Text] [Related]
8. Real-world biologic treatment and associated cost in patients with inflammatory bowel disease.
Brandes A; Groth A; Gottschalk F; Wilke T; Ratsch BA; Orzechowski HD; Fuchs A; Deiters B; Bokemeyer B
Z Gastroenterol; 2019 Jul; 57(7):843-851. PubMed ID: 31288280
[TBL] [Abstract][Full Text] [Related]
9. Direct health-care cost utilization in Hong Kong inflammatory bowel disease patients in the initial 2 years following diagnosis.
Mak LY; Ng SC; Wong IOL; Li MKK; Lo FH; Wong MTL; Leung CM; Tsang SWC; Chan KH; Sze SF; Shan EHS; Lam BCY; Hui AJ; Hung IFN; Leung WK
J Gastroenterol Hepatol; 2018 Jan; 33(1):141-149. PubMed ID: 28475813
[TBL] [Abstract][Full Text] [Related]
10. The Cost of Inflammatory Bowel Disease: An Initiative From the Crohn's & Colitis Foundation.
Park KT; Ehrlich OG; Allen JI; Meadows P; Szigethy EM; Henrichsen K; Kim SC; Lawton RC; Murphy SM; Regueiro M; Rubin DT; Engel-Nitz NM; Heller CA
Inflamm Bowel Dis; 2020 Jan; 26(1):1-10. PubMed ID: 31112238
[TBL] [Abstract][Full Text] [Related]
11. The cost of illness analysis of inflammatory bowel disease.
Pakdin M; Zarei L; Bagheri Lankarani K; Ghahramani S
BMC Gastroenterol; 2023 Jan; 23(1):21. PubMed ID: 36658489
[TBL] [Abstract][Full Text] [Related]
12. Economic Burden and Health Care Access for Patients With Inflammatory Bowel Diseases in China: Web-Based Survey Study.
Yu Q; Zhu C; Feng S; Xu L; Hu S; Chen H; Chen H; Yao S; Wang X; Chen Y
J Med Internet Res; 2021 Jan; 23(1):e20629. PubMed ID: 33399540
[TBL] [Abstract][Full Text] [Related]
13. A descriptive study of inflammatory bowel disease at an Egyptian tertiary care center.
El-Atrebi KA; Taher E; El Aguizy FH; Ali RM; Hegazy A; El-Sayed MM; Eysa B; El-Atreby AA; Mohammed AA; El-Bassyouni HT
Rev Gastroenterol Mex (Engl Ed); 2023; 88(1):12-18. PubMed ID: 34887218
[TBL] [Abstract][Full Text] [Related]
14. The pharmacoeconomics of biologic therapy for IBD.
Cohen RD
Nat Rev Gastroenterol Hepatol; 2010 Feb; 7(2):103-9. PubMed ID: 20134492
[TBL] [Abstract][Full Text] [Related]
15. Trends in the epidemiology of inflammatory bowel disease in Colombia by demographics and region using a nationally representative claims database and characterization of inflammatory bowel disease phenotype in a case series of Colombian patients.
Juliao-Baños F; Kock J; Arrubla M; Calixto O; Camargo J; Cruz L; Hurtado J; Clavijo A; Donado J; Schwartz S; Abreu MT; Damas OM
Medicine (Baltimore); 2021 Feb; 100(7):e24729. PubMed ID: 33607817
[TBL] [Abstract][Full Text] [Related]
16. The Impact of Inflammatory Bowel Disease in Canada 2018: Indirect Costs of IBD Care.
Kuenzig ME; Lee L; El-Matary W; Weizman AV; Benchimol EI; Kaplan GG; Nguyen GC; Bernstein CN; Bitton A; Lee K; Cooke-Lauder J; Murthy SK
J Can Assoc Gastroenterol; 2019 Feb; 2(Suppl 1):S34-S41. PubMed ID: 31294383
[TBL] [Abstract][Full Text] [Related]
17. Impact of the COVID-19 outbreak and the serum prevalence of SARS-CoV-2 antibodies in patients with inflammatory bowel disease treated with biologic drugs.
Bossa F; Carparelli S; Latiano A; Palmieri O; Tavano F; Panza A; Pastore M; Marseglia A; D'Altilia M; Latiano T; Corritore G; Martino G; Nardella M; Guerra M; Terracciano F; Sacco M; Perri F; Andriulli A
Dig Liver Dis; 2021 Mar; 53(3):277-282. PubMed ID: 33423942
[TBL] [Abstract][Full Text] [Related]
18. Drug utilization and cost associated with inflammatory bowel disease management in Saudi Arabia.
AlRuthia Y; Alharbi O; Aljebreen AM; Azzam NA; Almadi MA; Bahari OH; Almalki KA; Atham AT; Alanazi AS; Saeed M; HajkhderMullaissa B; Alsenaidy M; Balkhi B
Cost Eff Resour Alloc; 2019; 17():25. PubMed ID: 31827409
[TBL] [Abstract][Full Text] [Related]
19. Trends in health-care costs and utilization for inflammatory bowel disease from 2010 to 2014 in Korea: A nationwide population-based study.
Kim JW; Lee CK; Rhee SY; Oh CH; Shim JJ; Kim HJ
J Gastroenterol Hepatol; 2018 Apr; 33(4):847-854. PubMed ID: 29055148
[TBL] [Abstract][Full Text] [Related]
20. Characterization and prevalence of extraintestinal manifestations in a cohort of patients with inflammatory intestinal disease in Medellin, Colombia.
Juliao-Baños F; Arrubla M; Osorio L; Camargo J; Londoño J; Cáceres C; Carvajal J; Mosquera-Klinger G; Donado J
Gastroenterol Hepatol; 2021; 44(6):398-404. PubMed ID: 33172691
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
